Partnerships

The stem cell market is anticipated to be a $10 billion dollar industry by 2010. The national yearly spending for stem cell research in the U.S. currently exceeds $600 million. Approximately $600 million is also spent internationally (with China being the leader at $250 million), and California alone has pledged $3 billion over the next decade. On January 11, 2007, $48.5 million was authorized for non-profit and academic institutions alone. Fifty-seven U.S. academic institutions are currently conducting stem-cell research as well as at least 14 labs outside of the United States. 90% of research dollars has so far been spent on infrastructure and equipment. Acquisition of materials is now the new growth market.

Private stem cell companies have a huge market potential for licensing agreements with over ten known countries, 80 known companies, 70 known academic centers, and many others institutions applying or researching stem cell technology. The market potential will continue to grow as more users enter the space and more useful stem cell products become available as a result of concentrated research effort in this space.

Most of the existing stem cell companies are built around a single technology that addresses a single human disease/injury state. None possess technologies for generating human cell populations in quantity, quality or percentage purity that equals that of CSC. None create stem cell-derived human cell populations for license or sale. Thus, our differentiated stem cell products serve an unmet market need.

Live Cells on Demand!

California Stem Cell is now shipping high purity populations of fully characterized hESC-derived human cells in an ideal format for drug screening and predictive toxicology.
Learn more

More Information

Contact us for more information about partnership and investment opportunities with California Stem Cell